Loading...
NPI 1124361142 · Greenfield, WI · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ryan Vogel is a retina specialist (ophthalmology) physician provider located in Greenfield, Wisconsin. This profile covers 17 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Ryan Vogel |
| Address | 4131 W Loomis Rd Ste 240 |
| City | Greenfield |
| State | WI |
| ZIP | 53221 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | March 27, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $915.5K |
| Medicaid | $70.2K |
Practice is centered on retina-focused, in-office intravitreal therapy and associated imaging: the top two Medicare revenue drivers are drug injection codes J0178 (532 claims, $367.6K revenue; 40.2% of Medicare revenue) and J2777 (11K claims, $320.2K revenue; 35.0% of Medicare revenue), and the third is the injection procedure 67028 (675 claims, $58.1K; 6.3% of Medicare revenue). This mix — dominated by high-volume injectable drug administration and retina imaging codes such as 92134 (1.2K claims, $36.2K) — indicates the operation is primarily an office-based retina injection service with diagnostic imaging support.
Revenue concentration is pronounced for both payers: the top 3 Medicare codes account for 81.5% of total Medicare revenue and the top 3 Medicaid codes account for 95.6% of total Medicaid revenue. For Medicare the dominant drivers are J0178, J2777 and 67028, while for Medicaid the same procedural/retinal-injection codes (67028 and 92134) plus 92014 concentrate the bulk of payments, demonstrating a narrow revenue base centered on injections and retinal diagnostics.
The provider’s payer mix is heavily Medicare-weighted in scale: total Medicare revenue is $915.5K versus total Medicaid revenue of $70.2K, so Medicare is the overwhelmingly larger revenue source. Medicaid appears to be a much smaller component of volume and dollars, making this effectively a Medicare-centric practice in financial terms.
National competitive standing on the top drug codes is modest rather than dominant: J0178 ranks #1865 of 3204 nationally (42th percentile) and is labeled in the source as a "typical, unremarkable volume" for the code, while J2777 ranks #942 of 2039 (54th percentile) and is also described as typical. Those percentiles and labels indicate the provider is an active but not leading national injector of these agents.
Two non-drug codes indicate a stronger-than-typical role in initial evaluation and imaging: 92004 (new comprehensive ophthalmological evaluation) ranks #596 of 26467 (98th percentile) and is explicitly described as "notably above typical national volume," suggesting higher-than-typical new-patient consult activity; 92134 (retinal imaging) appears frequently on Medicare and is listed with 1.2K claims and is characterized in the file as "typical, unremarkable volume," despite a high percentile number, implying robust use of diagnostic imaging to support the injection practice.
Medicaid-level competitive standing is modest statewide: 67028 (511 claims, $49.1K; 70.7% of Medicaid revenue) ranks #19 of 30 in-state (38th percentile) and 92134 (1K claims, $13.5K; 19.4% of Medicaid revenue) ranks #21 of 52 (61th percentile). Those in-state ranks suggest the provider is a routine, not dominant, participant in Medicaid retina services within Wisconsin.
Operationally, the drug mix favors higher-cost, branded agents on Medicare: J0178 (aflibercept) and J2777 (faricimab) together generate the majority of Medicare drug revenue while J9035 (bevacizumab) contributes only $14.6K (1.6% of Medicare revenue) and is a minor revenue source for Medicaid as well ($1.6K, 2.4%). This pattern implies the practice bills more frequently for licensed anti-VEGF agents over bevacizumab in its Medicare population.
The provider shows established tenure: the NPI was enumerated (registered) on 2013-03-27 (~13 years ago), supporting that the observed billing profile reflects a multi-year, established retina practice rather than a short-term entrant. Combined with concentrated revenue streams and the mix of injections plus imaging, the profile fits a stable, procedure-driven retinal specialist practice serving predominantly Medicare beneficiaries.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 530 | $690 | $367.6K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 11,040 | $30 | $320.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 680 | $90 | $58K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 460 | $90 | $41.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,250 | $30 | $36.2K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 260 | $100 | $27K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 20 | $860 | $14.7K |
| J9035 | Injection, bevacizumab, 10 mg | 270 | $60 | $14.6K |
| 67041 | In this procedure, the provider removes scar tissue from the retinal membrane that obscures vision. He removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical… | 20 | $870 | $13K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 80 | $110 | $8.4K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 26 | 60 | 440 | $690 | $488.1K |
| J2777 | 7 | 30 | 7,290 | $30 | $332K |
| 67028 | 30 | 110 | 310 | $80 | $43.7K |
| 67042 | 13 | 20 | 20 | $870 | $20.8K |
| 67041 | 9 | 20 | 20 | $960 | $20.2K |
| J9035 | 24 | 70 | 110 | $50 | $14.5K |
| 92014 | 59 | 720 | 120 | $70 | $12.9K |
| 99214 | 7,405 | 9,800 | 80 | $70 | $9.2K |
| 92134 | 19 | 600 | 60 | $30 | $4.7K |
| 92235 | 9 | 30 | 50 | $70 | $4.5K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 510 | $100 | $49.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,040 | $10 | $13.5K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 210 | $20 | $3.8K |
| J9035 | Injection, bevacizumab, 10 mg | 40 | $40 | $1.6K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 90 | $20 | $1.4K |
How this provider's Medicaid billing volume and revenue compare to other Wisconsin providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Wisconsin median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 19 | 30 | 1,140 | $60 | $116.9K |
| J9035 | Injection, bevacizumab, 10 mg | 12 | 10 | 470 | $30 | $62.4K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 206 | 410 | 210 | $30 | $40.3K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 203 | 340 | 150 | $40 | $21.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 21 | 50 | 410 | $10 | $20.9K |
Other providers in the same ZIP code as Ryan Vogel, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.